Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 174 participants.

Also called NCT05054842

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05054842
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05054842. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-06 (actual); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
Intervention (Drug)
Retagliptin phosphate tablets、metformin sustained-release tablets
Intervention (Drug)
Retagliptin phosphate placebo tablets、metformin sustained-release tablets
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05054842
Content hash
d50f23a9d8d943b158da0b6007da37803fb89c33455c2d82ab3cff1c124bb315